Aevi Genomic Medicine, Inc.
CIK 0001138776
Revenue (TTM)
—
Q3 Nov 2019
Net Income (TTM)
−$19.78M
+8.6% YoY
Q3 Nov 2019
EPS Diluted (TTM)
$1.58
+16.7% YoY
Q3 Nov 2019
Gross Margin
—
Q3 Nov 2019
Operating Margin
—
Q3 Nov 2019
Net Margin
—
Q3 Nov 2019
Free Cash Flow (TTM)
−$14.95M
Q3 Nov 2019
Cash
$2.38M
Q3 Nov 2019
Total Debt
—
Q3 Nov 2019
Shares Outstanding
64.77M sh
Q3 Nov 2019
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.